• Most Popular
  • Most Shared

Keryx Biopharma enters into licensing agreement with Japan Tobacco and Torii Pharmaceutical

Wed Sep 26, 2007 7:15am EDT
Co announces that it entered into a licensing agreement with Japan Tobacco and Torii Pharmaceutical, JT's pharmaceutical business subsidiary, under which J. T. and Torii will hold the exclusive rights for the development and commercialization of its hyperphosphatemia drug in Japan... The licensing arrangement calls for J.T. and Torii to pay to KERX up to $100 mln in up-front license fees and payments upon the achievement of pre-specified milestones, including up to $20 mln in up- front payments and near-term milestones. In addition, upon commercialization, J.T. and Torii will make royalty payments to KERX on net sales of the drug in Japan. J.T. and Torii will be responsible for the future development and commercialization costs in Japan.



More from Reuters

Joint Terminal Attack Controller SSgt Clinton J. Herbison, a U.S. Airman from the 817 Expeditionary Air Support Operations Squadron (EASOS) takes a break during a night mission near Honaker Miracle camp at the Pesh valley of Kunar Province August 12, 2009. Credit: REUTERS/Carlos Barria

Pictures of the Year

A look at the best photos of 2009.  Slideshow 

    PICTURES
    The Dalai Lama jokes with a nasal spray after being asked his opinion on the swine flu during a press conference after his first lecture in Lausanne, Switzerland, August 4, 2009. REUTERS/ Valentin Flauraud

    What a wacky year it's been...

    Um, what's up the Dalai Lama's nose? "Oddly Enough" editor Bob Basler rounds up the goofiest photos of the year.  Full Article 

    Oddly Enough
    A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
    Political Risk in 2010:

    Don't say we didn't warn you

    With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

    Global Markets